Our R&D capabilities
Medix Biochemica’s scientific professionals have decades of experience on the development of essential raw materials for diagnostic applications.
With 1 of 4 employees dedicated to design and development of new products, we are able to keep up with the cutting-edge of all aspects of the IVD industry — from native and recombinant antibodies and antigens to molecular diagnostic reagents. Our customer-centric approach makes us the ideal partner to meet your needs.
Our R&D and analytical teams also utilize their expertise to develop assay methods, purification schemes, and tailor or scale up processes to deliver the right product and solutions for our clients’ final application.
Please get in touch with us today to discuss your bespoke needs
Monoclonal antibody development
Medix Biochemica has been a pioneer in monoclonal antibody development since the late 1970’s. We have world-leading expertise in developing novel antibodies for all types of molecules relevant in IVD, both with mouse hybridoma and phage display technologies. Our R&D professionals also have thorough knowledge and experience on the adaptation of antibody-producing cell lines to industrial scale animal-free manufacturing processes.
State-of-the-art recombinant technologies are also used in our product development department to develop engineered antibodies. We rescue antibodies from hybridomas to recombinant form and switch the domains between different species when needed. We analyze antibody structures computationally and engineer them for enhanced performance, to ensure our customers will have the best options available for their IVD tests.
Our R&D team has unique experience on the development of fully scalable processes for the purification of native proteins from a range of different animal and human materials. A wide spectrum of extraction and chromatography methods are used to develop enrichment and purification protocols for native enzymes, antigens, and other proteins, also in situations where the natural abundance of the target protein is very low in the original source material.
We develop recombinant proteins for calibrator and control products, or for use as critical raw materials in serological tests. Both bacterial and mammalian expression hosts are used, for optimal expression and functionality.
Molecular Diagnostic reagents
Our experienced Molecular Diagnostics R&D team works on the development of a broad range of platform-agnostic reagents, and provides expert advice, instruments, and software for assay development. Discover MedixMDx.
Monoclonal antibodies, native, and recombinant proteins are carefully characterized with a comprehensive selection of analytical tools in our R&D laboratories. The biochemical and functional properties are studied by various chromatographic, electrophoretic, enzymatic, immunochemical, cytometric, and kinetic analyses.
Latest R&D updates
Keeping up with cutting-edge protein analytics? – We IVDo that
Our Protein Biochemistry R&D group is proud to share their latest publication developed together with an international team of 18 biopharmaceutical and in vitro diagnostics companies, and one regulatory agency. The next-generation imaged CIEF instrument evaluated in the study is routinely used in our laboratory, enabling high-precision homogeneity analyses in antibody development and quality control.
Production of recombinant antibodies for IVD applications
Medix Biochemica’s diagnostic antibody development toolbox is wide, spanning from mouse hybridomas to chimeric recombinant mAbs. R&D Scientist Emilia Galli, Ph.D, presented our latest results on the production of recombinant antibodies for IVD applications at the Antibody Engineering & Therapeutics Europe event in Amsterdam in June 2022.